HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Archive

All News

Every briefing, headline, and filing we've published, newest first.

In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
PipelineFiercePharma ↗
After prevailing in two kidney cancer trials in the refractory and early-stage settings, Merck & Co.’s blo…
Apr 22, 2026
UCB Buys Neurona for $650M to Deepen Epilepsy Bet
DealsBriefing
UCB’s $650 million deal for Neurona Therapeutics signals a move to blend neurology heritage with next‑gen cell…
Apr 22, 2026
BioAegis and Prenosis partner for inflammatory disease therapies
The WeekPharmaceutical Technology ↗
BioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicin…
Apr 22, 2026
STAT+: Insurers refuse to join Medicare pilot offering weight loss drugs to seniors at steep discount
PolicySTAT News ↗
Health insurers would have likely faced a financial strain by participating in the Medicare pilot.…
Apr 21, 2026
FDA approves once-daily HIV pill from Merck
PipelineEndpoints News ↗
A new HIV treatment will soon come to market, and it will spearhead Merck’s attempt to be one of the leading d…
Apr 21, 2026
Medicaid Waiver Tracker: Approved and Pending Section 1115 Waivers by State
PolicyKFF Health News ↗
Section 1115 Medicaid waivers can allow states to test new approaches in Medicaid that differ from what is req…
Apr 21, 2026
DataDrug Channels ↗
By Adam J. Fein, Ph.D.Drug Channels Institute’s (DCI’s) latest analysis reveals that PBM-affiliated specialty …
Apr 21, 2026
Lilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7B
DealsFierceBiotech ↗
Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for…
Apr 21, 2026
Trump orders FDA to fast-track reviews of psychedelic drugs after lobbying by podcaster
PolicyFiercePharma ↗
President Donald Trump has ordered the FDA to perform priority reviews of psychedelic drugs as part of a push …
Apr 21, 2026
RFK Jr. Backs 12% HHS Budget Cut as GOP Voices Split on NIH Impact
PolicyBriefing
HHS Secretary Robert F. Kennedy Jr. defended a proposed $16B budget cut, including $5B from NIH, as Republican…
Apr 21, 2026
Asahi Kasei acquires German company Aicuris
DealsPharmaceutical Technology ↗
Asahi Kasei has completed its acquisition of Aicuris Anti-infective Cures, a German biopharmaceutical company.…
Apr 21, 2026
STAT+: At AACR, a provocative use of CAR-T, Merck’s new thing and cancer’s geography problem
PipelineSTAT News ↗
At AACR, a bold use of CAR-T raises hopes and provocative questions about its use in smoldering multiple myelo…
Apr 20, 2026
Trump, FDA plan to expedite psychedelic development
PolicyEndpoints News ↗
Over the weekend, President Donald Trump endorsed the potential of psychedelic treatments and vowed to expedit…
Apr 20, 2026
Boehringer Ingelheim to expand its AI footprint in UK, in £150M investment
DealsEndpoints News ↗
LONDON – Boehringer Ingelheim is growing its artificial intelligence arm to the UK by building a new hub in ce…
Apr 20, 2026
Lilly Bets $3.25B on Kelonia to Push In‑Vivo CAR‑T from Concept to Platform
Deals
Lilly’s $3.25 billion upfront acquisition of Kelonia Therapeutics signals a bold move into in‑vivo CAR‑T techn…
Apr 20, 2026
Who is Dr. Houman Hemmati, potentially CBER’s next leader?
PeoplePharmaVoice ↗
Where the rumored frontrunner stands on key issues like vaccines and public health policy.…
Apr 20, 2026
Trump orders FDA to fast-track reviews of psychedelic drugs after lobbying by podcaster
PolicyFierceBiotech ↗
President Donald Trump has ordered the FDA to perform priority reviews of psychedelic drugs as part of a push …
Apr 20, 2026
Merck Gains EU Clearance for Enflonsia, a Long-Acting RSV Antibody for Infants
PipelineBriefing
Enflonsia, now cleared across the EU and EEA, promises single-dose, five-month protection against RSV, positio…
Apr 20, 2026
What actually drives speed in complex drug development programs
PipelineBioPharma Dive ↗
Learn how early coordination across functions, phases and partners can reduce risk and accelerate drug develop…
Apr 20, 2026
Odyssey Therapeutics will try again to IPO, this time in a warmer market
MoneyEndpoints News ↗
A year after pulling its first try at an IPO, Odyssey Therapeutics is giving it another go. On Friday night, t…
Apr 20, 2026
STAT+: AACR 2026: More strong data for Revolution Medicines’ KRAS drug
PipelineSTAT News ↗
You're reading the web version of STAT's popup newsletter, AACR in 30 seconds, your guide to what's happening …
Apr 19, 2026
Teva launches new online schizophrenia community project
PeopleFiercePharma ↗
Just two months after the FDA accepted for review Teva’s long-acting version of a decades-old schizophrenia dr…
Apr 18, 2026
Omnicom brews Olixir from FCB Health, rebranding storied agency after Interpublic takeover
PeopleFiercePharma ↗
Omnicom Health has stamped its mark on the recently acquired FCB Health New York, rebranding the ad agency as …
Apr 18, 2026
Astellas manufacturing chief views reliable supply, bridging research as his production 'north star'
PeopleFiercePharma ↗
For Astellas’ chief manufacturing officer, Rao Mantri, Ph.D., production is not just about a reliable supply o…
Apr 18, 2026
← Newer Page 12 Older →
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.